

# Analysis of genes linked to depressive-like behaviors in interleukin-18-deficient mice: Gene expression profiles in the brain

KYOSUKE YAMANISHI<sup>1,2</sup>, TAKUYA HASHIMOTO<sup>2</sup>, MASAHIRO MIYAUCHI<sup>2</sup>, KEIICHIRO MUKAI<sup>2</sup>,  
KAORU IKUBO<sup>2</sup>, NORIKO UWA<sup>2</sup>, YUKO WATANABE<sup>3</sup>, TAKASHI IKAWA<sup>3</sup>, DAISUKE OKUZAKI<sup>4</sup>,  
HARUKI OKAMURA<sup>1,3</sup>, HIROMICHI YAMANISHI<sup>3</sup> and HISATO MATSUNAGA<sup>1,2</sup>

Departments of <sup>1</sup>Psychoimmunology and <sup>2</sup>Neuropsychiatry, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501;  
<sup>3</sup>Hirakata General Hospital for Developmental Disorders, Hirakata, Osaka 573-0122; <sup>4</sup>Genome Information Research Center,  
Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan

Received August 7, 2019; Accepted October 23, 2019

DOI: 10.3892/br.2019.1259

**Abstract.** Interleukin (IL)-18 is an interferon  $\gamma$ -inducing inflammatory cytokine associated with function of the immune system and other physiological functions. IL-18-deficient (*Il18*<sup>-/-</sup>) mice exhibit obesity, dyslipidemia, non-alcoholic steatohepatitis and depressive-like behavioral changes. Therefore, IL-18 has a number of important roles associated with immunity, energy homeostasis and psychiatric conditions. In the present study, gene expression in the brains of *Il18*<sup>-/-</sup> mice was analyzed to identify genes associated with the depressive-like behaviors and other impairments displayed by *Il18*<sup>-/-</sup> mice. Using whole genome microarray analysis, gene expression patterns in the brains of *Il18*<sup>+/+</sup> and *Il18*<sup>-/-</sup> mice at 6 and 12 weeks of age were examined and compared. Subsequently, genes were categorized using Ingenuity® Pathway Analysis (IPA). At 12 weeks of age, 2,805 genes were identified using microarray analysis. Genes related to 'Major depression' and 'Depressive disorders' were identified by IPA core analysis, and 13 genes associated with depression were isolated. Among these genes, fibroblast growth factor receptor 1 (*Fgfr1*); protein tyrosine phosphatase, non-receptor type 1 (*Ptpn1*); and urocortin 3 (*Ucn3*) were classed as depression-inducing and the other genes were considered depression-suppressing genes. Subsequently, the interactions between the microarray results at 6 weeks of age and the above three depression-inducing genes were analyzed to search for effector genes of depression at 12 weeks of age. This analysis identified cyclin D1 (*Ccnd1*) and NADPH oxidase 4 (*Nox4*). The microarray analysis results were correlated with the results of reverse transcription-quantitative PCR (RT-qPCR).

Overall, the results suggest that *Fgfr1*, *Ptpn1* and *Ucn3* may be involved in depression-like changes and *Ccnd1* and *Nox4* regulate these three genes in IL-18-deficient mice.

## Introduction

Major depressive disorder (MDD) has a high worldwide prevalence. Several hypotheses regarding the mechanism of development of MDD have been proposed, including an immunological mechanism involving cytokines (1,2). Increased levels of proinflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), have been identified in patients with MDD by meta-analyses (3). Clinical trials of a cyclooxygenase-2 inhibitor to suppress inflammation in patients with MDD produced symptomatic improvements; however, the immunological mechanisms underlying MDD are not understood in detail.

IL-18 was initially identified as an interferon- $\gamma$  inducing factor (4). An inactive 24-kDa precursor form of IL-18 is cleaved by activated caspase-1 to a mature 18-kDa active form (4-7). In addition to its role as an inflammatory cytokine, IL-18 also serves a role in energy metabolism, and in the central nervous system it is involved in psychiatric disorders such as depression (8-12). Regarding energy homeostasis, IL-18 deficiency induces bulimia, corpulency and insulin resistance which resembles type 2 diabetes mellitus (8). IL-18-deficient mice also exhibit dyslipidemia leading to nonalcoholic fatty liver disease and steatohepatitis (9), and hippocampal impairments that may cause depression-like behavioral changes (12). Therefore, IL-18 is closely related to energy homeostasis, central nervous system function, and the occurrence of psychiatric disorders such as depression. However, the biological mechanism by which IL-18 contributes to these processes remains unclear.

In our previous study (12), it was demonstrated that the aforementioned behavioral changes were the result of hippocampal impairments; however, other parts of the brain, including the prefrontal cortex and amygdala, are also responsible for depression (13,14). Therefore, to determine the biological and molecular mechanisms responsible for depression caused by IL-18 deficiency, additional analyses of other brain regions are required.

**Correspondence to:** Professor Hisato Matsunaga, Department of Neuropsychiatry, Hyogo College of Medicine, 1-1 Mukogawa, Nishinomiya, Hyogo 663-8501, Japan  
E-mail: hisa1311@hyo-med.ac.jp

**Key words:** interleukin-18, depression, learning and memory, brain, major depressive disorder

In the present study, candidate genes which may be involved in the induction of depressive-like behavioral changes were identified by comparing gene expression in the brains of *Il18<sup>+/+</sup>* and *Il18<sup>-/-</sup>* mice. At 12 weeks of age, a time at which *Il18<sup>-/-</sup>* mice start to exhibit depression-like behavioral changes, the genes with a  $>1.5$ -fold change were identified and analyzed using Ingenuity® Pathway Analysis (IPA) as described previously (10,11). Subsequently, to explore candidate genes associated with depression at 12 weeks of age, microarray analysis was performed to compare expression at 6 and 12 weeks of age to screen for effector genes that induce depression. Finally, to confirm the microarray results, reverse transcription-quantitative PCR (RT-qPCR) was performed.

## Materials and methods

Details regarding RNA purification, microarray analysis, RT-qPCR, and IPA (Ingenuity® Systems; ingenuity.com) have been described in our previous studies (15-17).

**Animals.** *Il18<sup>-/-</sup>* C57BL/6 male mice were used in the present study (18). Littermate *Il18<sup>+/+</sup>* male mice were used as the controls. Mice were housed in groups of 3-5 in polycarbonate cages in a controlled environment (temperature,  $22\pm1^{\circ}\text{C}$ ; humidity, 50-60%; and a 12-h light/dark cycle) with free access to water and food (MF; Oriental Yeast Co., Ltd.). A total of three *Il18<sup>+/+</sup>* and three *Il18<sup>-/-</sup>* mice were used for microarray and RT-qPCR analysis.

Animal experiments performed in the present study were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health and approved by the Animal Care Committee of Hyogo College of Medicine (Hyogo, Japan; approval nos. #28041, #13-062, #14-020 and #16-013) prior to performing the animal experiments.

**Sample collection.** Mice were euthanized by deep anesthesia using 5% isoflurane inhalation at 10:00 a.m., and lack of ventilation was used to confirm euthanasia. The brains were removed and immediately placed in liquid nitrogen and subsequently kept at  $-80^{\circ}\text{C}$  until required.

**RNA purification.** Total RNA was extracted and purified from mice brains using a Sepasol-RNA I Super kit (Nacalai Tesque, Inc.) according to the manufacturer's protocol. Genomic DNA contamination was removed using 5 units RNase free DNase I at  $37^{\circ}\text{C}$  for 30 min. After phenol/chloroform extraction and ethanol precipitation, total RNA was dissolved in de-ionized water. RNA concentrations were measured using NanoDrop 1000 spectrophotometry (NanoDrop Technologies; Thermo Fisher Scientific, Inc.).

**Microarray analysis.** Expression profiling was performed as described previously (9). Raw data were imported into Subio platform version 1.18 (Subio, Inc.) and normalized. Differentially expressed genes between *Il18<sup>+/+</sup>* and *Il18<sup>-/-</sup>* mouse brains were defined by signal ratios of  $>1.5$ -fold. Data can be accessed in Gene Expression Omnibus (accession no. GSE64307).

**Heatmap design.** Heatmaps were created using the regHeatmap function of the Heatplus package (heatmaps with row and/or column covariates and colored clusters; github.com/alexploner/Heatplus) in R version 2.30.0.

**IPA.** IPA (version spring 2019) was used to determine the functionality of microarray results and for the interpreting the gene profiling data. To investigate molecular mechanisms affected by IL-18 expression, core analysis was performed with the following settings: Tissue, Brain; all other settings, default. The network explorer of IPA was used to detect relevant interactions among genes extracted at 6 and 12 weeks of age and to reveal the shortest direct pathways between genes without protein-protein interactions.

**RT-qPCR.** Brain samples from mice at 6 or 12 weeks of age were used for analysis of expression. A total of 5 ng/reaction total RNA was used, extracted as described above and was analyzed using RNA-direct SYBR-Green Real-Time PCR Master mix and a One-step qPCR kit (Toyobo Life Science). Samples were run in duplicate reactions in 384-well plates. Median threshold cycle values were used to calculate the fold changes between group samples. The fold change values were normalized to *Gapdh* levels using the relative standard curve method. qPCR was performed using QuantiStudio™ 12K Flex (Thermo Fisher Scientific, Inc.). The reverse transcription and thermocycling conditions were:  $90^{\circ}\text{C}$  for 30 sec and 20 min at  $61^{\circ}\text{C}$  for reverse transcription; followed by 45 cycles of  $98^{\circ}\text{C}$  for 1 sec,  $67^{\circ}\text{C}$  for 15 sec and  $74^{\circ}\text{C}$  for 35 sec. The primer sequences for RT-qPCR are shown in Table I.

**Statistical analysis.** All results are expressed as the mean  $\pm$  standard deviation. Sigmaplot™ (version 11.0; Systat Software, Inc.) was used for all statistical analyses. The microarray results were analyzed using a Student's t-test and correlations between the microarray and RT-qPCR results were analyzed using Spearman's rank correlation tests. All analyses were performed  $>2$  times to confirm the results.  $P<0.05$  was considered to indicate a statistically significant difference.

## Results

**Identification and categorization of differentially expressed genes in *Il18<sup>-/-</sup>* mice.** The heatmaps of the microarray results at 6 and 12 weeks of age are shown in Fig. 1A and B, respectively. A total of 699 and 2,805 genes showed a  $>1.5$ -fold-change (*Il18<sup>-/-</sup>/Il18<sup>+/+</sup>*) in expression at 6 and 12 weeks of age, respectively, and were extracted for further analysis. The results of IPA core analysis are shown in Table II. Based on the results of IPA, 13 genes associated with 'Major depression' and 'Depressive disorder' were identified: Aquaporin 4 (*Aqp4*), BTG anti-proliferation factor (*Btg1*), *Btg2*, CD46, chromogranin A, complexin 1, corticotropin releasing hormone, eukaryotic translation initiation factor 6, fibroblast growth factor receptor 1 (*Fgfr1*), hepatocyte growth factor-regulated tyrosine kinase substrate (*Hgs*), kinesin family member 5B (*Kif5b*), protein tyrosine phosphatase, non-receptor type 1 (*Ptpn1*) and urocortin 3 (*Ucn3*). The heatmap of extracted genes is shown in Fig. 1C.

Table I. Primer sequences.

Gene (GenBank Accession no.)	Sequence, 5'-3'
<i>Aqp4</i> (NM_009700)	
Forward	CTTCCGCCCATCGAATGCTC
Reverse	CGACATTTGCAGCACATTGTCT
<i>Bdnf</i> (NM_007540)	
Forward	CGCCCATGAAAGAAGTAAACGTCCA
Reverse	GGCCCATTCACGCTCTCC
<i>Btg1</i> (NM_007569)	
Forward	GGCTTTGTCCGCATTTCCATAGCAG
Reverse	CTTTGCCCATGAGGTACACGTT
<i>Btg2</i> (NM_007570)	
Forward	CTGCCTCCTGGTCTCATGCTT
Reverse	ACAGTCCAGCTCTAGGGTTT
<i>Cd46</i> (NM_010778)	
Forward	GCCTACTCATCCTACCAAGCCT
Reverse	TTGGCTAAATATTCCTTCACGGGGAC
<i>Chga</i> (NM_007693)	
Forward	CCAATACCCAATCACCAACCAGC
Reverse	TCTCACTGTCTCCCGTGGC
<i>Cplx1</i> (NM_007756)	
Forward	TCTGCAAGGTTTGGCTTAAGAATTCCA
Reverse	ACCCGCTCCAAATCTATTGCT
<i>Crh</i> (NM_205769)	
Forward	AGAGAGCCTATATACCCCTTAATTAGCAT
Reverse	AGCATGGGCAATACAAATAACGC
<i>Drp2</i> (NM_010078)	
Forward	CCACAACAAGCAGCTCGAGT
Reverse	GAGCCATTGCCATCTGATTCACT
<i>Eif6</i> (NM_010579)	
Forward	CACCCTAAAACTTCTATCGAGGACCA
Reverse	CCTCGGTTACAGTGCCT
<i>Fgfr1</i> (NM_010206)	
Forward	ATCATAATGGATTCTGTGGTGCCT
Reverse	CTCATTCTCCACGATGCAGGT
<i>Gapdh</i> (NM_008084)	
Forward	CCTTCCGTGTTCTACCCCCAAT
Reverse	TTGATGTCATCATACTTGGCAGGTTTCTC
<i>Hgs</i> (NM_001159328)	
Forward	GACTCTCAGCCCATAACTCCCT
Reverse	CTCATGGCTCTCCTCCGACT
<i>Htr2c</i> (NM_008312)	
Forward	GCATACCAATGAACGTGTAGTTAGGAA
Reverse	GGCAGCTCTAAATTCTCTACCTGCATC
<i>Kif5b</i> (NM_008448)	
Forward	CTCACGGTTATGCAAGACAGACGA
Reverse	CACGGTCTCCTCCAAACCC
<i>Ptpn1</i> (NM_011201)	
Forward	AACTGGAGCCTCACAACGG
Reverse	CCAGGCTGTCTTCATCCCC

Table I. Continued.

Gene (GenBank Accession no.)	Sequence, 5'-3'
<i>Ucn3</i> (NM_031250)	
Forward	GGGCACCAAGTTCACCCTT
Reverse	CGCAAATTCTTGGCCTTGTCG

*Aqp4*, aquaporin 4; *Bdnf*, brain derived neurotrophic factor; *Btg*, BTG anti-proliferation factor; *Chga*, chromogranin A; *Cplx1*, complexin 1; *Crh*, corticotropin releasing hormone; *Drp2*, Dystrophin Related Protein 2; *Eif6*, eukaryotic translation 6; *Hgs*, hepatocyte growth factor-regulated tyrosine kinase substrate; *Ucn3*, urocortin 3; *Fgfr1*, fibroblast growth factor receptor 1; *Ptpn1*, protein tyrosine phosphatase, non-receptor type 1; *Kif5b*, kinesin family member 5B; *Htr2c*, 5-hydroxytryptamine receptor 2C.




Figure 1. Heatmap analyses of gene expression profiles between *IL18*<sup>+/+</sup> and *IL18*<sup>-/-</sup> mice. Heatmap of microarray results at (A) 6 and (B) 12 weeks of age. (C) Heatmap of 13 extracted genes associated with depression at 12 weeks of age. The levels of gene expression are shown in different colors, which transition from green to red with increasing expressions. IL, interleukin; *Aqp4*, aquaporin 4; *Btg*, BTG anti-proliferation factor; *Chga*, chromogranin A; *Cplx1*, complexin 1; *Crh*, corticotropin releasing hormone; *Eif6*, eukaryotic translation 6; *Hgs*, hepatocyte growth factor-regulated tyrosine kinase substrate; *Ucn3*, urocortin 3; *Fgfr1*, fibroblast growth factor receptor 1; *Ptpn1*, protein tyrosine phosphatase, non-receptor type 1; *Kif5b*, kinesin family member 5B.

*Interactions between depression-associated genes and IL18*<sup>-/-</sup>-specific genes at 6 weeks of age. Interaction pathway analysis was used to identify genes responsible for regulating

Table II. Disease association or functional annotation of differentially expressed genes at 12 weeks of age based on Ingenuity Pathway Analysis.

Diseases or function annotation	P-value	No. of genes
Demyelination	0.00817	5
Neuropathy of brain	0.0130	3
Despair behavior	0.0135	2
Fear memory acquisition	0.0135	2
Apoptosis of anterior pituitary cells	0.0135	2
Childhood adrenoleukodystrophy	0.0135	2
Feeding	0.0219	8
Astrocytoma	0.0221	41
Anorexia	0.0238	3
Grade 1-4 astrocytoma	0.0255	40
Abnormal morphology of molecular layer of cerebellum	0.0304	5
Major depression	0.0357	12
Brain astrocytoma	0.0367	39
Depressive disorder	0.0375	13
Apoptosis of neural precursor cells	0.0381	3
Injury of cortical neurons	0.0381	3
Movement disorders	0.0388	44
Emotional behavior	0.0433	8
Central nervous system neuroepithelial tumor	0.0434	48
High grade astrocytoma	0.0444	38
Glioma	0.0454	48
Abnormality of cerebral cortex	0.0467	38
Glioma cancer	0.0472	44
Low grade astrocytoma	0.0491	5

depression-associated genes. As shown in Fig. 2, the interactions deemed to be significant in the pathway analysis are shown for 10 genes: Adenosine A2a receptor (*Adora2a*), cyclin D1 (*Ccnd1*), CCAAT enhancer binding protein delta, D-box binding PAR bZIP transcription factor, endothelin 1, Fos proto-oncogene, AP-1 transcription factor subunit, FosB proto-oncogene, AP-1 transcription factor subunit,




Figure 2. Pathway analysis amongst the depression-associated molecules at 12 weeks of age and their effector genes at 6 weeks of age. Interactions between 13 depression-inducing genes at 12 weeks of age and *Il18*<sup>-/-</sup>-specific genes at 6 weeks of age were analyzed. The figure indicates the associations between genes. Solid and dotted lines represent direct and indirect associations, respectively.

HRas proto-oncogene, GTPase, *Notch1* and NADPH oxidase 4 (*Nox4*).

**Depression-inducing genes in *Il18*<sup>-/-</sup> mice at 12 weeks of age.** The 13 genes extracted in mice 12 weeks of age were separated into depression-inducing and depression-suppressing genes based on previous studies (19-21). Among these 13 genes, *Fgfr1*, *Ptpn1* and *Ucn3* may be associated with the development of MDD (depression-inducing), whereas the other 10 genes may be depression-suppressing genes in MDD.

**Interactions between depression-inducing and -suppressing genes at 12 weeks of age with the 10 extracted genes at 6 weeks of age.** The interactions between the three depression-inducing genes at 12 weeks of age, *Fgfr1*, *Ptpn1* and *Ucn3*, and 10 genes at 6 weeks of age were examined and it was found that *Ccnd1* and *Nox4* may affect development of depression. *Ccnd1* inhibition increases the expression of *Fgfr1* (22), and *Nox4* decreases *Ptpn1* expression (23).

**Correlation between microarray and RT-qPCR results.** To confirm the microarray analysis results, RT-qPCR was performed, and a correlation test was performed between the results of the microarray analysis and RT-qPCR (Table III). To determine the correlation between microarray and RT-qPCR analysis, Spearman's rank correlation coefficient analysis was performed for each group (6-week-old group:  $P=0.014$ ,  $\rho=0.60$ ; 12-week-old group:  $P=0.007$ ,  $\rho=0.64$ ; Fig. 3).

## Discussion

The present study identified potentially novel IL-18 pathways in the brain based on the core analysis, 13 genes were identified to be associated with depression at 12 weeks of age; in particular, *Fgfr1*, *Ptpn1* and *Ucn3* which may be responsible for causing depression in *Il18*<sup>-/-</sup> mice. *Ccnd1* and *Nox4* at 6 weeks of age interacted with *Fgfr1* and *Ptpn1*, indicating that

Table III. Comparison of microarray and RT-qPCR gene expression data at 6 and 12 weeks of age.

A, 6 weeks of age		
Gene symbol	FC (RT-qPCR)	FC (Microarray)
<i>Aqp4</i>	0.875	0.808
<i>Bdnf</i>	1.074	1.190
<i>Btg1</i>	0.702	0.651
<i>Btg2</i>	1.255	1.470
<i>Cd46</i>	1.249	1.312
<i>Chga</i>	0.631	0.980
<i>Cplx1</i>	0.714	1.029
<i>Crh</i>	0.817	1.290
<i>Drp2</i>	0.931	1.311
<i>Eif6</i>	0.834	1.143
<i>Fgfr1</i>	0.743	0.963
<i>Hgs</i>	1.019	1.145
<i>Htr2c</i>	0.768	0.684
<i>Kif5b</i>	0.875	0.636
<i>Ptpn1</i>	1.059	1.237
<i>Ucn3</i>	0.758	1.280

## B, 12 weeks of age

Gene symbol	FC (RT-qPCR)	FC (Microarray)
<i>Aqp4</i>	0.665	0.481
<i>Bdnf</i>	1.247	1.014
<i>Btg1</i>	0.558	0.813
<i>Btg2</i>	0.625	0.552
<i>Cd46</i>	0.611	0.563
<i>Chga</i>	1.085	1.594
<i>Cplx1</i>	1.148	1.604
<i>Crh</i>	1.165	1.742
<i>Drp2</i>	1.431	1.202
<i>Eif6</i>	0.890	0.965
<i>Fgfr1</i>	0.922	1.610
<i>Hgs</i>	1.036	1.618
<i>Htr2c</i>	0.645	0.872
<i>Kif5b</i>	0.808	0.524
<i>Ptpn1</i>	1.542	1.336
<i>Ucn3</i>	1.328	1.609

*Aqp4*, aquaporin 4; *Bdnf*, brain derived neurotrophic factor; *Btg1*, BTG anti-proliferation factor; *Chga*, chromogranin A; *Cplx1*, complexin 1; *Crh*, corticotropin releasing hormone; *Drp2*, Dystrophin Related Protein 2; *Eif6*, eukaryotic translation initiation factor 6; *Fgfr1*, fibroblast growth factor receptor 1; *Hgs*, hepatocyte growth factor-regulated tyrosine kinase substrate; *Htr2c*, 5-hydroxytryptamine receptor 2C; *Kif5b*, kinesin family member 5B; *Ptpn1*, protein tyrosine phosphatase, non-receptor type 1; *Ucn3*, urocortin 3; RT-qPCR, reverse transcription quantitative polymerase chain reaction; FC (RT-qPCR), fold change based on the results obtained from RT-qPCR; FC (microarray), fold change based on the results obtained from microarray analysis.




Figure 3. Correlation plots between the results of microarray analysis and RT-qPCR at (A) 6 ( $P=0.014$ ,  $\rho=0.60$ ) and (B) 12 weeks of age ( $P=0.007$ ,  $\rho=0.64$ ). RT-qPCR, reverse transcription-quantitative PCR.

*Ccnd1* and *Nox4* may be causative genes and the microarray and RT-qPCR results were significantly correlated.

In our previous study, impaired learning and memory, and depressive-like behavioral changes in *Il18*<sup>-/-</sup> mice at 12 weeks of age were observed (12). To identify the genes responsible for *IL18* associated depression, microarray analysis of gene expression in brains from *Il18*<sup>+/+</sup> and *Il18*<sup>-/-</sup> mice and IPA core analysis were performed using previously described procedures (17). In the core analysis results, the function and annotation of ‘Major depression’ and ‘Depressive disorder’ were generated automatically. From the microarray results, 13 genes at 12 weeks of age were associated with ‘depression’. Among these 13 genes, three, *Fgfr1*, *Ptpn1* and *Ucn3*, have previously been causally associated with ‘Major depression’ and ‘Depressive disorder’ (19,21). *Fgfr1* has been implicated in the development of the brain and self-renewal of neural precursor cells (24,25). In *Il18*<sup>-/-</sup> mice, neurogenesis is decreased (12); therefore, the increased expression of *Fgfr1* may be a compensatory response to the decrease in neurons during a depressive state. *Ptpn1* serves a role in negatively regulating insulin signaling. *Ptpn1* deficiency increases insulin sensitivity and obesity resistance (26). In the present study, in the *Il18*<sup>-/-</sup> mice, the expression of *Ptpn1* was increased, and it has previously been shown that *IL18*<sup>-/-</sup> mice exhibit insulin resistance and obesity (8). *Ucn3* is associated with stress-induced anxiety and depression, and with energy homeostasis. Expression of *Ucn3* in the rostral perifornical area of the brain regulates not only anxiety-like behaviors but also glucose metabolism of the body (27,28). The expression of *Ucn3* in *Il18*<sup>-/-</sup> mice at 12 weeks of age was increased; thus, a deficiency in IL-18 might increase the expression of *Ptpn1* and *Ucn3*, resulting in not only depressive-like behavioral changes but also in an energy imbalance. Additionally, in clinical studies on patients with MDD, the mRNA expression levels of *Fgfr1*, *Ptpn1* and *Ucn3* were increased in the prefrontal cortex compared with healthy controls (19,21). The expression of *Fgfr1*, *Ptpn1* and *Ucn3* in *Il18*<sup>-/-</sup> mice at 12 weeks of age was higher compared with the *Il18*<sup>+/+</sup> mice based on the microarray results. The localization of expression of these genes were determined using the BrainStars database (brainstars.org) (29). *Fgfr1* expression is upregulated in the pontine nucleus and

hippocampus, *Ptpn1* is expressed in the anterior olfactory bulb and hippocampus, and *Ucn3* is expressed in the paraventricular hypothalamic nucleus and amygdala. Together, these results suggest that these three genes are expressed in the brain and are involved in depression.

In contrast to these three genes, the other 10 genes identified may have the opposite effect on depression, according to previous findings (19,20,30). For example, upregulated *Aqp4* expression in the prefrontal cortex was associated with MDD in patients. However, the expression of *Aqp4* in *Il18*<sup>-/-</sup> mice was decreased, and the other nine genes also exhibited similar changes. Therefore, these results suggest the existence of a negative feedback process in MDD.

To analyze the molecular regulation of the three genes at 12 weeks of age (*Fgfr1*, *Ptpn1*, and *Ucn3*), interaction pathway analysis was performed, and based on the results, *Ccnd1* and *Nox4* were extracted. Inhibition of *Ccnd1* expression increases *Fgfr1* mRNA levels in humans (31) and reduced expression of *Nox4*-activated PTPN1 protein expression in humans (23). These findings suggest that *Ccnd1* and *Nox4* may regulate expression of *Fgfr1* and *Ptpn1*, and thus may be responsible for inducing a depressive state in IL-18 deficiency.

In our previous study, it was shown that decreased expression of *Ccnd1* in the liver of *Il18*<sup>-/-</sup> mice at 6 and 12 weeks of age may be causally associated with energy imbalance through the Wnt signaling pathway (9). In the present study, a similar change was observed in *Il18*<sup>-/-</sup> mice at 6 weeks of age. Wnt signaling is indispensable for hippocampal memory function (32) and is also associated with depressive symptoms in an animal model of depression (33). Accordingly, *Ccnd1* may regulate energy levels and depression in *Il18*<sup>-/-</sup> mice.

Another gene extracted at 6 weeks of age, *Adora2a*, also affected *Kif5b* expression at 12 weeks of age. The expression of *Adora2a* was increased and *Kif5b* was decreased, and *Adora2a* inhibition may have decreased *Kif5b* expression in the present study, which differs from the results of a previous study (34). Neuroinflammation is significantly associated with MDD. In particular, inflammatory cytokines, such as TNF- $\alpha$ , have been identified as mediators of MDD by impairing the function of the blood brain barrier (35-37). Increased *Adora2a* expression

in cerebral endothelial cells may induce blood-brain barrier leakage resulting in the impairment of hippocampal memory function (38). Therefore, these findings indicate that increased expression of *Adora2a* at 6 weeks of age may be responsible for inducing the behavioral phenotypes of *Il18*<sup>-/-</sup> mice through neuroinflammation.

To assess the correlation between the microarray and RT-qPCR results, Spearman's rank correlation coefficient analysis was performed, and a significant correlation was detected between the results.

A limitation of the present study was that the molecular analysis was performed using whole brains; therefore, genes affected by IL-18 only in select areas may not have been detected, and further molecular studies using specific parts of the brain are thus warranted. In addition, a more notable limitation is that the present study did not analyze protein expression levels encoded for by the identified genes. The identified genes may be associated with depression; however the protein expression and protein localization in the brain are required to determine interactions between IL-18 and the proteins encoded for by the extracted genes. Additionally, further studies using *in vitro* and *in vivo* models are also required.

In conclusion, the gene expression profile of *Il18*<sup>-/-</sup> mice brain was examined and an association between the expression of certain genes and a depressive phenotype in mice was identified. *Fgfr1*, *Ptpn1* and *Ucn3* may be associated with depression, and may be regulated by *Ccnd1* and *Nox4*. Furthermore, *Adora2a* and *Ccnd1* may contribute to depression when expression of IL-18 is downregulated.

In our previous study, it was hypothesized that IL-18 may serve as a novel option for treatment of metabolic disorders, such as diabetes mellitus and dyslipidemia, and for neuropsychiatric disorders, such as MDD (9,11,12). The results of the present study support the notion that IL-18 may serve as a novel treatment strategy of metabolic and neuropsychiatric disorders, including MDD.

## Acknowledgements

The authors would like to thank Mr. Nobutaka Okamura and Mrs. Naomi Gamachi for their technical support, Mr. Nobutaka Okamura for his assistance with animal care and the collection of samples, and Mrs. Naomi Gamachi for assistance with the experiments.

## Funding

The present study was supported by JSPS KAKENHI (grant no. JP17K16404) and by the Takeda Science Foundation (2019).

## Availability of data and materials

The datasets shown and/or analyzed in the present study are available from the corresponding author on reasonable request.

## Authors' contributions

KY and HM designed the study. TH, MM, KM, KI, NU, TI, and DO performed experiments. YW, HO, and HY analyzed

the data. KY and HM wrote the manuscript. All authors read and approved the final manuscript.

## Ethics approval and consent to participate

Animal experiments were approved by the Animal Care Committee of Hyogo College of Medicine (Hyogo, Japan; approval nos. #28041, #13-062, #14-020, and #16-013) prior to beginning animal experiments.

## Patient consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## References

1. Maes M: Major depression and activation of the inflammatory response system. *Adv Exp Med Biol* 461: 25-46, 1999.
2. Yirmiya R, Weidenfeld J, Pollak Y, Morag M, Morag A, Avitsur R, Barak O, Reichenberg A, Cohen E, Shavit Y and Ovadia H: Cytokines, 'depression due to a general medical condition' and antidepressant drugs. *Adv Exp Med Biol* 461: 283-316, 1999.
3. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK and Lancôt KL: A meta-analysis of cytokines in major depression. *Biol Psychiatry* 67: 446-457, 2010.
4. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, *et al*: Cloning of a new cytokine that induces IFN-gamma production by T cells. *Nature* 378: 88-91, 1995.
5. Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T and Nakanishi K: Interleukin-18: A novel cytokine that augments both innate and acquired immunity. *Adv Immunol* 70: 281-312, 1998.
6. Tsutsui H, Kayagaki N, Kuida K, Nakano H, Hayashi N, Takeda K, Matsui K, Kashiwamura S, Hada T, Akira S, *et al*: Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. *Immunity* 11: 359-367, 1999.
7. Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A, Quintal L, Sekut L, Talanian R, Paskind M, *et al*: Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. *Nature* 386: 619-623, 1997.
8. Netea MG, Joosten LA, Lewis E, Jensen DR, Voshol PJ, Kullberg BJ, Tack CJ, van Krieken H, Kim SH, Stalenhoef AF, *et al*: Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. *Nat Med* 12: 650-656, 2006.
9. Yamanishi K, Maeda S, Kuwahara-Otani S, Watanabe Y, Yoshida M, Ikubo K, Okuzaki D, El-Darawish Y, Li W, Nakasho K, *et al*: Interleukin-18-deficient mice develop dyslipidemia resulting in nonalcoholic fatty liver disease and steatohepatitis. *Transl Res* 173: 101-114.e7, 2016.
10. Yamanishi K, Mukai K, Hashimoto T, Ikubo K, Nakasho K, El-Darawish Y, Li W, Okuzaki D, Watanabe Y, Hayakawa T, *et al*: Physiological and molecular effects of interleukin-18 administration on the mouse kidney. *J Transl Med* 16: 51, 2018.
11. Yamanishi K, Maeda S, Kuwahara-Otani S, Hashimoto T, Ikubo K, Mukai K, Nakasho K, Gamachi N, El-Darawish Y, Li W, *et al*: Deficiency in interleukin-18 promotes differentiation of brown adipose tissue resulting in fat accumulation despite dyslipidemia. *J Transl Med* 16: 314, 2018.
12. Yamanishi K, Doe N, Mukai K, Ikubo K, Hashimoto T, Uwa N, Sumida M, El-Darawish Y, Gamachi N, Li W, *et al*: Interleukin-18-deficient mice develop hippocampal abnormalities related to possible depressive-like behaviors. *Neuroscience* 408: 147-160, 2019.
13. Amat J, Baratta MV, Paul E, Bland ST, Watkins LR and Maier SF: Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. *Nat Neurosci* 8: 365-371, 2005.

14. Hamilton JP, Siemer M and Gotlib IH: Amygdala volume in major depressive disorder: A meta-analysis of magnetic resonance imaging studies. *Mol Psychiatry* 13: 993-1000, 2008.
15. Yamanishi K, Doe N, Sumida M, Watanabe Y, Yoshida M, Yamamoto H, Xu Y, Li W, Yamanishi H, Okamura H and Matsunaga H: Hepatocyte nuclear factor 4 alpha is a key factor related to depression and physiological homeostasis in the mouse brain. *PLoS One* 10: e0119021, 2015.
16. Ikubo K, Yamanishi K, Doe N, Hashimoto T, Sumida M, Watanabe Y, El-Darawish Y, Li W, Okamura H, Yamanishi H and Matsunaga H: Molecular analysis of the mouse brain exposed to chronic mild stress: The influence of hepatocyte nuclear factor 4 $\alpha$  on physiological homeostasis. *Mol Med Rep* 16: 301-309, 2017.
17. Yoshida M, Watanabe Y, Yamanishi K, Yamashita A, Yamamoto H, Okuzaki D, Shimada K, Nojima H, Yasunaga T, Okamura H, *et al*: Analysis of genes causing hypertension and stroke in spontaneously hypertensive rats: Gene expression profiles in the brain. *Int J Mol Med* 33: 887-896, 2014.
18. Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T, Okamura H, Nakanishi K and Akira S: Defective NK cell activity and Th1 response in IL-18-deficient mice. *Immunity* 8: 383-390, 1998.
19. Tochigi M, Iwamoto K, Bundo M, Sasaki T, Kato N and Kato T: Gene expression profiling of major depression and suicide in the prefrontal cortex of postmortem brains. *Neurosci Res* 60: 184-191, 2008.
20. Tezval H, Jahn O, Todorovic C, Sasse A, Eckart K and Spiess J: Cortagine, a specific agonist of corticotropin-releasing factor receptor subtype 1, is anxiogenic and antidepressive in the mouse model. *Proc Natl Acad Sci USA* 101: 9468-9473, 2004.
21. Kang HJ, Adams DH, Simen A, Simen BB, Rajkowska G, Stockmeier CA, Overholser JC, Meltzer HY, Jurjus GJ, Konick LC, *et al*: Gene expression profiling in postmortem prefrontal cortex of major depressive disorder. *J Neurosci* 27: 13329-13340, 2007.
22. Tashiro E, Maruki H, Minato Y, Doki Y, Weinstein IB and Imoto M: Overexpression of cyclin D1 contributes to malignancy by up-regulation of fibroblast growth factor receptor 1 via the pRB/E2F pathway. *Cancer Res* 63: 424-431, 2003.
23. Mahadev K, Motoshima H, Wu X, Ruddy JM, Arnold RS, Cheng G, Lambeth JD and Goldstein BJ: The NAD(P)H oxidase homolog Nox4 modulates insulin-stimulated generation of H<sub>2</sub>O<sub>2</sub> and plays an integral role in insulin signal transduction. *Mol Cell Biol* 24: 1844-1854, 2004.
24. Trokovic R, Trokovic N, Hernesniemi S, Pirvola U, Vogt Weisenhorn DM, Rossant J, McMahon AP, Wurst W and Partanen J: FGFR1 is independently required in both developing mid- and hindbrain for sustained response to isthmus signals. *EMBO J* 22: 1811-1823, 2003.
25. Stevens HE, Smith KM, Maragnoli ME, Fagel D, Borok E, Shanabrough M, Horvath TL and Vaccarino FM: Fgfr2 is required for the development of the medial prefrontal cortex and its connections with limbic circuits. *J Neurosci* 30: 5590-5602, 2010.
26. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J, Chan CC, *et al*: Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. *Science* 283: 1544-1548, 1999.
27. Kuperman Y, Issler O, Regev L, Musseri I, Navon I, Neufeld-Cohen A, Gil S and Chen A: Perifornical Urocortin-3 mediates the link between stress-induced anxiety and energy homeostasis. *Proc Natl Acad Sci USA* 107: 8393-8398, 2010.
28. Li C, Chen P, Vaughan J, Lee KF and Vale W: Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis. *Proc Natl Acad Sci USA* 104: 4206-4211, 2007.
29. Kasukawa T, Masumoto KH, Nikaido I, Nagano M, Uno KD, Tsujino K, Hanashima C, Shigeyoshi Y and Ueda H: Quantitative expression profile of distinct functional regions in the adult mouse brain. *PLoS One* 6: e23228, 2011.
30. Sawada K, Young CE, Barr AM, Longworth K, Takahashi S, Arango V, Mann JJ, Dwork AJ, Falkai P, Phillips AG and Honer WG: Altered immunoreactivity of complexin protein in prefrontal cortex in severe mental illness. *Mol Psychiatry* 7: 484-492, 2002.
31. Chen G, Wang J, Liu Z and Kornmann M: Exon III splicing of fibroblast growth factor receptor 1 is modulated by growth factors and cyclin D1. *Pancreas* 37: 159-164, 2008.
32. Fortress AM, Schram SL, Tuscher JJ and Frick KM: Canonical Wnt signaling is necessary for object recognition memory consolidation. *J Neurosci* 33: 12619-12626, 2013.
33. Hui J, Zhang J, Pu M, Zhou X, Dong L, Mao X, Shi G, Zou J, Wu J, Jiang D and Xi G: Modulation of GSK-3 $\beta$ / $\beta$ -catenin signaling contributes to learning and memory impairment in a rat model of depression. *Int J Neuropsychopharmacol* 21: 858-870, 2018.
34. Yu L, Haverty PM, Mariani J, Wang Y, Shen HY, Schwarzschild MA, Weng Z and Chen JF: Genetic and pharmacological inactivation of adenosine A2A receptor reveals an Egr-2-mediated transcriptional regulatory network in the mouse striatum. *Physiol Genomics* 23: 89-102, 2005.
35. Krishnadas R and Cavanagh J: Depression: An inflammatory illness? *J Neurol Neurosurg Psychiatry* 83: 495-502, 2012.
36. Khairova RA, Machado-Vieira R, Du J and Manji HK: A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. *Int J Neuropsychopharmacol* 12: 561-578, 2009.
37. Liu H, Luiten PG, Eisel UL, Dejongste MJ and Schoemaker RG: Depression after myocardial infarction: TNF- $\alpha$ -induced alterations of the blood-brain barrier and its putative therapeutic implications. *Neurosci Biobehav Rev* 37: 561-572, 2013.
38. Yamamoto M, Guo DH, Hernandez CM and Stranahan AM: Endothelial Adora2a activation promotes blood-brain barrier breakdown and cognitive impairment in mice with diet-induced insulin resistance. *J Neurosci* 39: 4179-4192, 2019.